More Headaches For Philips As FDA Labels Another Ventilator Recall As High-Risk Class I
Executive Summary
The recalled vents are designed to provide high-flow therapy to patients, but problems can crop up “if the system pressure reaches the default maximum limit,” the US agency says. The recall is more bad news for Philips, which recently initiated a separate class I recall of certain breathing and ventilator devices.
You may also be interested in...
Philips Commits To ESG And AI While Servicing Respironics Recall Priority
Royal Philips CEO Roy Jakobs used the company’s 2023 results conference to update the market on the agile operating plan 2023-2025 and US actions to address the Respironics recall. Investors’ lively interest in the recall meant that strategic themes concerning environmental sustainability and future health care dividends from artificial intelligence platforms were all but sidelined.
Philips Doubles Down On ESG And AI While Servicing Respironics Recall Priority
Royal Philips CEO Roy Jakobs used the company’s 2023 results conference to update the market on the agile operating plan 2023-2025 and US actions to address the Respironics recall. Investors’ lively interest in the recall meant that strategic themes concerning environmental sustainability and future health care dividends from artificial intelligence platforms were all but sidelined.
Philips Agrees Terms Of US Consent Decree, Remains Bullish On 2024
Royal Philips CEO Roy Jakobs updated investors on progress of the company’s operating plan 2023-25, US actions and litigation on the Respironics portfolio, patient safety, quality and the order book as it announced Q4 2023 revenues.